Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments.
Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Moderna reaffirms 2025 revenue guidance of $1.5 billion–$2.5 billion, cuts 2027 cost forecast by up to $1.7 billion, and targets 2026 approval for its flu/COVID combo shot.
The company reported first-quarter revenue of $108 million, down from $167 million in the corresponding period of 2024, and below an analyst estimate of $115.32 million, as per FinChat data.
Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue guidance of $2 billion at the midpoint came in 6.1% below analysts’ estimates. Its GAAP loss of $2.52 per share was 18.6% above analysts’ consensus estimates.
The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting other manufacturers.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 12.7%. This drop was worse than the S&P 500’s 7.5% loss.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Stocks in the U.S. were trading sharply lower by midday Monday, while gold and Bitcoin (CRYPTO: BTC) surged in tandem, as a renewed political storm surrounding Federal Reserve independence shook confidence in the U.S.
“Buy the dip” strategies are hard to get right, but they can yield phenomenal results. Now, TradeSmith believes they’ve found a way to help longer-term investors find attractive entry points into great long-term stocks. Today, I’ve been given permission to share five picks from their breakthrough AI system, An-E.
